Top

Molecular Imaging and Biology

Published in:

01-02-2010 | Research Article

Visualization of Somatostatin Receptors in Prostate Cancer and its Bone Metastases with Ga-68–DOTATOC PET/CT

Authors: Wolfgang Luboldt, Klaus Zöphel, Gerd Wunderlich, Andrij Abramyuk, Hans-Joachim Luboldt, Joerg Kotzerke

Published in: Molecular Imaging and Biology | Issue 1/2010

Abstract

Purpose

To assess DOTATOC-affine somatostatin receptor expression in advanced prostate cancer and its bone metastases with regard to DOTATOC-mediated receptor therapies, using a Ga-68–DOTATOC PET/CT.

Procedures

Twenty consecutive patients with advanced prostate cancer underwent bone scintigraphy, followed by Ga-68–DOTATOC PET/CT within 3 weeks. Through side-by-side comparison with bone scintigraphy, the number of visible bone metastases on PET was determined. In addition, in cases of visible metastases, the maximum standard uptake value (SUV_max) of Ga-68–DOTATOC was measured in the metastases and in normal bone. In patients who did not undergo a prostatectomy (n = 12), the SUV_max was additionally measured in the prostate and in adjacent tissue. For focal lesions, the difference in SUV_max (ΔSUV_max) between the metastases and normal bone was calculated. For patients still having their prostate, a ΔSUV_max between the prostate and its adjacent tissue was calculated.

Results

Sixty four of 216 metastases (30%) were visible in 13 patients with focal metastases. Of six patients with diffuse metastases (superscan), one showed diffuse metastases, three showed a total of ten focal metastases, and two showed no correlate on PET. One patient with a neuroendocrine prostate cancer showed no correlate on PET. The maximum ΔSUV_max between metastases and normal bone was 4.9 (mean = 1.6 ± 0.9) and between the prostate and adjacent tissue 5.9 (mean = 2.8 ± 1.6).

Conclusions

In prostate cancer and its bone metastases, DOTATOC-affine somatostatin receptors (subtype 2 and 5) can be visualized with Ga-68–DOTATOC PET/CT. But their expression is so weak that other conjugates should be tested for receptor-mediated therapies which are better at addressing the prostate cancer-specific somatostatin receptor subtypes 1 and 4—or even other receptors.

Heidenreich A, Ohlmann CH (2005) Treatment options for hormone-refractory prostate cancer. Urologe A 44(11):1303–4, 1306–14

Schmid HP, Gregorin J, Altwein JE (2008) Growth hormone inhibitors in prostate cancer: a systematic analysis. Urol Int 81(1):17–22CrossRefPubMed

Kwekkeboom DJ, Kooij PP, Bakker WH, Macke HR, Krenning EP (1999) Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J Nucl Med 40(5):762–767PubMed

Cremonesi M, Ferrari M, Zoboli S et al (1999) Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC. Eur J Nucl Med 26(8):877–886CrossRefPubMed

Chinol M, Bodei L, Cremonesi M, Paganelli G (2002) Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group. Semin Nucl Med 32(2):141–147CrossRefPubMed

Forrer F, Waldherr C, Maecke HR, Mueller-Brand J (2006) Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res 26(1B):703–707PubMed

Forrer F, Valkema R, Kwekkeboom DJ, de Jong M, Krenning EP (2007) Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab 21(1):111–129CrossRefPubMed

Zhernosekov KP, Filosofov DV, Baum RP et al (2007) Processing of generator-produced 68Ga for medical application. J Nucl Med 48(10):1741–1748 Epub 2007 Sep 14CrossRefPubMed

Heidenreich A, Aus G, Bolla M et al (2008) EAU guidelines on prostate cancer. Eur Urol 53(1):68–80CrossRefPubMed

10.

Koutsilieris M, Mitsiades CS, Bogdanos J et al (2004) Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases. Clin Cancer Res 10(13):4398–4405CrossRefPubMed

11.

Mitsiades CS, Bogdanos J, Karamanolakis D, Milathianakis C, Dimopoulos T, Koutsilieris M (2006) Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer. Anticancer Res 26(5B):3693–3700PubMed

12.

Reisine T, Bell GI (1995) Molecular biology of somatostatin receptors. Endocr Rev 16(4):427–442PubMed

13.

Reubi JC, Waser B, Schaer JC, Laissue JA (2001) Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 28(7):836–846CrossRefPubMed

14.

Hansson J, Bjartell A, Gadaleanu V, Dizeyi N, Abrahamsson PA (2002) Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer. Prostate 53(1):50–59CrossRefPubMed

15.

Sciarra A, Bosman C, Monti G et al (2004) Somatostatin analogues and estrogens in the treatment of androgen ablation refractory prostate adenocarcinoma. J Urol 172(5 Pt 1):1775–1783CrossRefPubMed

16.

Kosari F, Munz JM, Savci-Heijink CD et al (2008) Identification of prognostic biomarkers for prostate cancer. Clin Cancer Res 14(6):1734–1743CrossRefPubMed

17.

Koutsilieris M, Tzanela M, Dimopoulos T (1999) Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone-refractory prostate cancer: case report. Prostate 38(4):313–316CrossRefPubMed

18.

Koppan M, Nagy A, Schally AV, Arencibia JM, Plonowski A, Halmos G (1998) Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses. Cancer Res 58(18):4132–4137PubMed

19.

Krijnen JL, Janssen PJ, Ruizeveld de Winter JA, van Krimpen H, Schroder FH, van der Kwast TH (1993) Do neuroendocrine cells in human prostate cancer express androgen receptor. Histochemistry 100(5):393–398CrossRefPubMed

20.

Di Sant'Agnese PA, Cockett AT (1994) The prostatic endocrine-paracrine (neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: a review and future directions in basic research. J Urol 152(5 Pt 2):1927–1931PubMed

21.

Abrahamsson PA (1999) Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer 6(4):503–519CrossRefPubMed

22.

Kwekkeboom DJ, Mueller-Brand J, Paganelli G et al (2005) Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 46(Suppl 1):62S–66SPubMed

23.

Nilsson S, Reubi JC, Kalkner KM et al (1995) Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [¹¹¹In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy. Cancer Res 55(23 Suppl):5805s–5810sPubMed

24.

Hofmann M, Maecke H, Borner R et al (2001) Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 28(12):1751–1757CrossRefPubMed

25.

Gabriel M, Decristoforo C, Kendler D et al (2007) 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48(4):508–518CrossRefPubMed

26.

Buchmann I, Henze M, Engelbrecht S et al (2007) Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 34(10):1617–1626CrossRefPubMed

27.

Dizeyi N, Konrad L, Bjartell A et al (2002) Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines. Urol Oncol 7(3):91–98CrossRefPubMed

28.

Schuhmacher J, Zhang H, Doll J et al (2005) GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6–14) analog. J Nucl Med 46(4):691–699PubMed

29.

Breeman WA, de Jong M, Erion JL et al (2002) Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med 43(12):1650–1656PubMed

30.

Miederer M, Seidl S, Buck A et al (2009) Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in (68)Ga–DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 36(1):48–52CrossRefPubMed

31.

Cimitan M, Buonadonna A, Cannizzaro R et al (2003) Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role. Ann Oncol 14(7):1135–1141CrossRefPubMed

32.

Namwongprom S, Wong FC, Tateishi U, Kim EE, Boonyaprapa S (2008) Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors. Ann Nucl Med 22(4):237–243CrossRefPubMed

33.

Zophel K, Strumpf A, Wunderlich G, Oehme L, Eisenhofer G, Kotzerke J (2008) Cure of neuroendocrine carcinoma by peptide receptor radionuclide therapy. Clin Nucl Med 33(10):690–691CrossRefPubMed

34.

Bodei L, Cremonesi M, Grana C et al (2004) Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 31(7):1038–1046CrossRefPubMed

Title: Visualization of Somatostatin Receptors in Prostate Cancer and its Bone Metastases with Ga-68–DOTATOC PET/CT
Authors: Wolfgang Luboldt
Klaus Zöphel
Gerd Wunderlich
Andrij Abramyuk
Hans-Joachim Luboldt
Joerg Kotzerke
Publication date: 01-02-2010
Publisher: Springer-Verlag
Published in: Molecular Imaging and Biology / Issue 1/2010
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-009-0230-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Visualization of Somatostatin Receptors in Prostate Cancer and its Bone Metastases with Ga-68–DOTATOC PET/CT

Abstract

Purpose

Procedures

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Procedures

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2010

Evaluation of the Radiocobalt-Labeled [MMA-DOTA-Cys61]-ZHER2:2395-Cys Affibody Molecule for Targeting of HER2-Expressing Tumors

The Use of F-18 Choline PET in the Assessment of Bone Metastases in Prostate Cancer: Correlation with Morphological Changes on CT

Intravital Imaging of Tumor Apoptosis with FRET Probes During Tumor Therapy

Comparison of Gene-Transfer Efficiency in Human Embryonic Stem Cells

Bioluminescence Imaging in Mouse Models Quantifies β Cell Mass in the Pancreas and After Islet Transplantation

Involvement of Nigrostriatal Pathway in Japanese Encephalitis with Movement Disorders: Evidence from 99mTc-TRODAT-1 and 123I-IBZM SPECT Imagings